Novel Immune Engagers and Cellular Therapies for Metastatic Castration-Resistant Prostate Cancer: Do we take a BiTe or ride BiKEs, TriKEs, and CARs?

BACKGROUND: Checkpoint inhibitors and currently approved cellular products for metastatic castration-resistant prostate cancer have not resulted in the revolutionary changes in outcomes compared to other solid tumors. Much of this lack of progress is attributed to the unique tumor microenvironment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zorko, Nicholas A., Ryan, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613314/
https://www.ncbi.nlm.nih.gov/pubmed/34035459
http://dx.doi.org/10.1038/s41391-021-00381-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613314/
https://www.ncbi.nlm.nih.gov/pubmed/34035459
http://dx.doi.org/10.1038/s41391-021-00381-w

Ejemplares similares